Quintin Lai - West Pharmaceutical President
| WST Stock | USD 227.51 2.88 1.25% |
President
Dr. Quintin J. Lai, Ph.D., is Vice President, Corporationrationrate Development, Strategy and Investor Relations of the company. He is Vice President, Corporationrationrate Development, Strategy and Investor Relations since January 2016. Prior to joining West, he was Vice President of Investor Relations and Corporationrationrate Strategy at SigmaAldrich Corporation from 2012 to 2015. From 2002 to 2012, he was at Robert W. Baird Company, where he held various roles, including Managing Director and Senior Equity Research Analyst of the Life Science Tools and Diagnostic sector and Associate Director of Equity Research. since 2016.
| Age | 53 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 530 Herman O. West Drive, Exton, PA, United States, 19341-1147 |
| Phone | 610 594 2900 |
| Web | https://www.westpharma.com |
Quintin Lai Latest Insider Activity
Tracking and analyzing the buying and selling activities of Quintin Lai against West Pharmaceutical stock is an integral part of due diligence when investing in West Pharmaceutical. Quintin Lai insider activity provides valuable insight into whether West Pharmaceutical is net buyers or sellers over its current business cycle. Note, West Pharmaceutical insiders must abide by specific rules, including filing SEC forms every time they buy or sell West Pharmaceutical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Quintin Lai over six months ago Acquisition by Quintin Lai of 1388 shares of West Pharmaceutical at 274.29 subject to Rule 16b-3 |
West Pharmaceutical Management Efficiency
The company has Return on Asset of 0.0993 % which means that on every $100 spent on assets, it made $0.0993 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1771 %, implying that it generated $0.1771 on every 100 dollars invested. West Pharmaceutical's management efficiency ratios could be used to measure how well West Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, West Pharmaceutical's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.14 in 2025, whereas Return On Capital Employed is likely to drop 0.10 in 2025. At this time, West Pharmaceutical's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 3.8 B in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 311.4 M in 2025.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| James Borzi | Becton Dickinson and | 49 | |
| Roger Graham | Teleflex Incorporated | N/A | |
| Cristiano Franzi | Baxter International | 61 | |
| Jennifer Schneiders | Hologic | 57 | |
| Cameron Hicks | Teleflex Incorporated | 60 | |
| Alexandre Conroy | Becton Dickinson and | 57 | |
| James Ferguson | Teleflex Incorporated | N/A | |
| James Darecca | Haemonetics | 50 | |
| Jeanne Mason | Baxter International | 69 | |
| Jan Verstreken | Hologic | 57 | |
| Andrew Frye | Baxter International | 59 | |
| Jake Newman | Teleflex Incorporated | N/A | |
| Ralf Kuriyel | Repligen | 67 | |
| Alberto Mas | Becton Dickinson and | 59 | |
| Brian Andrews | The Cooper Companies, | 45 | |
| SueJean Lin | Alcon AG | 65 | |
| Sean Martin | Baxter International | 58 | |
| Robert Douglas | ResMed Inc | 64 | |
| Christopher Reidy | Becton Dickinson and | 64 | |
| Brik Eyre | Baxter International | 54 | |
| James Saccaro | Baxter International | 51 | |
Management Performance
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0993 |
West Pharmaceutical Leadership Team
Elected by the shareholders, the West Pharmaceutical's board of directors comprises two types of representatives: West Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of West. The board's role is to monitor West Pharmaceutical's management team and ensure that shareholders' interests are well served. West Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, West Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Buthman, Independent Director | ||
| Deborah Tanner, Independent Director | ||
| Bernard Birkett, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer | ||
| Eric Green, President, Chief Executive Officer, Director | ||
| John CFA, Head Relations | ||
| Rudy Poussot, Senior Development | ||
| Kathy DePadua, Senior Officer | ||
| Dr CFA, Vice Relations | ||
| William Feehery, Independent Director | ||
| Aileen RuffPatry, President Manufacturing | ||
| Robert Friel, Independent Director | ||
| Richard Luzzi, VP HR | ||
| Myla LaiGoldman, Independent Director | ||
| Paula Johnson, Independent Director | ||
| Douglas Michels, Independent Director | ||
| Michele Polinsky, Vice Communications | ||
| Kimberly MacKay, Senior Vice President General Counsel, Corporate Secretary | ||
| Don OCallaghan, President Devices | ||
| Paolo Pucci, Independent Director | ||
| Annette Favorite, Chief Human Resource Officer, Senior Vice President | ||
| Patrick Zenner, Independent Chairman of the Board | ||
| Thomas Hofmann, Independent Director | ||
| Silji Abraham, Senior Vice President and Chief Digital and Transformation Officer | ||
| David Montecalvo, Senior Vice President, Chief Operating and Supply Chain Officer | ||
| Christopher Ryan, Senior Vice President of Commercial Products and Emerging Markets | ||
| Quintin Lai, Vice President - Corporate Development, Strategy and Investor Relations | ||
| Molly Joseph, Director | ||
| Andy Polywacz, President Systems | ||
| George Miller, Senior Vice President General Counsel, Corporate Secretary | ||
| Charles CPA, VP Treasurer | ||
| Cindy ReissClark, Senior Vice President of Global Market Units and Commercial Solutions | ||
| Chad Winters, Chief Accounting Officer, Principal Accounting Officer, Vice President, Corporate Controller | ||
| Robert Segura, VP Devel | ||
| Eric Resnick, Chief Technology Officer, Vice President |
West Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is West Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0993 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 16.48 B | ||||
| Shares Outstanding | 72.3 M | ||||
| Shares Owned By Insiders | 0.59 % | ||||
| Shares Owned By Institutions | 97.21 % | ||||
| Number Of Shares Shorted | 1.37 M | ||||
| Price To Earning | 40.71 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.